Moderna, Inc. (NASDAQ:MRNA – Get Free Report) rose 3.4% during trading on Tuesday. The company traded as high as $235.50 and last traded at $228.44. Approximately 9,477,924 shares traded hands during trading, a decline of 25% from the average session volume of 12,619,756 shares. The stock had previously closed at $220.83.
Trending Headlines about Moderna
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: Moderna and Merck’s personalized cancer vaccine, intismeran, showed promising late-stage melanoma results when used with Keytruda, reducing the risk of death or recurrence by 42%. The data strengthens the potential long-term value of Moderna’s pipeline, though the treatment still faces development and approval hurdles. Article: Moderna’s Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
- Neutral Sentiment: Moderna is scheduled to report third-quarter results before the market opens Nov. 6. Analysts expect $888.8 million in sales and a loss of $1.37 per share, making the report a near-term catalyst. Article: Buy Moderna Stock Before Q3 Earnings? Here’s What to Know
- Neutral Sentiment: Prediction markets are placing bets on the timing of FDA action for the melanoma vaccine, highlighting investor focus on regulatory milestones. The article raises concerns about potential information leakage but reports no new FDA decision. Article: What Is Moderna Answering As FDA Vaccine Betting Markets Grow?
- Negative Sentiment: Coverage notes that Moderna’s shares have rallied sharply and carry a premium valuation ahead of earnings. That can leave less room for disappointment if results or the outlook fail to meet investor expectations. Article: Buy Moderna Stock Before Q3 Earnings? Here’s What to Know
Analysts Set New Price Targets
A number of research firms recently weighed in on MRNA. The Goldman Sachs Group upped their target price on shares of Moderna from $120.00 to $137.00 and gave the stock a “neutral” rating in a report on Thursday, October 15th. Bradesco Corretora upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. Evercore upped their price objective on shares of Moderna from $50.00 to $80.00 in a research note on Thursday, October 8th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Moderna in a research note on Friday, September 25th. Finally, Citigroup reaffirmed a “sell” rating on shares of Moderna in a research report on Friday, October 23rd. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $107.10.
Moderna Trading Up 3.4%
The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $184.00 and a 200 day simple moving average of $87.42. The firm has a market capitalization of $91.20 billion, a P/E ratio of -28.59 and a beta of 1.09.
Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The business had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter last year, the business posted ($2.13) EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. As a group, research analysts forecast that Moderna, Inc. will post -6.11 EPS for the current year.
Insider Activity
In other Moderna news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 197,251 shares of company stock valued at $33,875,904. Corporate insiders own 10.80% of the company’s stock.
Institutional Trading of Moderna
Several hedge funds and other institutional investors have recently bought and sold shares of MRNA. Costello Asset Management INC raised its position in Moderna by 7.3% during the third quarter. Costello Asset Management INC now owns 966 shares of the company’s stock worth $186,000 after acquiring an additional 66 shares during the period. Physician Wealth Advisors Inc. raised its position in shares of Moderna by 8.3% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock valued at $171,000 after buying an additional 68 shares during the period. Fortitude Family Office LLC grew its holdings in shares of Moderna by 53.1% during the 3rd quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after purchasing an additional 77 shares during the period. TD Waterhouse Canada Inc. boosted its position in shares of Moderna by 2.6% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock worth $246,000 after purchasing an additional 85 shares during the period. Finally, SteelPeak Wealth LLC lifted its stake in Moderna by 3.9% during the 3rd quarter. SteelPeak Wealth LLC now owns 3,397 shares of the company’s stock worth $654,000 after acquiring an additional 127 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.
Moderna Company Profile
Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.
Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.
See Also
- Five stocks we like better than Moderna
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
